Insights / Technology
Posts carrying the In-Silico Clinical Trials tag.
30 Apr 2026 · 3 min read
The FDA's first real-time clinical trials don't just promise faster reviews — they insert a new infrastructure layer between sponsors and the agency. I break down what that architectural shift means for clinical development.
5 Jan 2026 · 2 min read
I'm sharing my 5 bets for AI in Healthcare and TechBio in 2026 — from ambient scribes becoming table stakes to a TechBio Series B shakeout accelerating. If one of these is wrong, I want to know which one and what would change your mind.
1 Dec 2025 · 2 min read
MIT just open-sourced BoltzGen, a generative AI for protein binder design — but I don't think it disrupts AI drug discovery companies any more than Linux killed software. The moat was never the model; it's proprietary data, wet-lab validation, and pharma relationships.
6 Oct 2025 · 1 min read
I attended an inspiring talk from Sergei Yakneen, CTO at Isomorphic Labs, at BiotechX2025 in Basel — and it's clear that Google's Alphabet subsidiary is really onto something with their AlphaFold3-powered approach to AI drug discovery at scale.
6 Oct 2025 · 1 min read
I attended an exciting panel on GenAI's impact in preclinical development, featuring voices from Novartis, Insilico Medicine, and INVIDIA. Key themes included the balance of AI opportunity and risk, the power of robotics combined with AI, and the ongoing challenge of data organization and institutional memory in the lab.
25 Sept 2025 · 1 min read
The NHS is building AIR-SP, a national AI screening cloud that lets every trust plug into shared, real-world trials — starting with a breast-cancer study involving nearly 700,000 women. I think the overall approach makes sense, and I'd love to see other countries adopt something similar.
13 Feb 2025 · 1 min read
I explore whether AI is truly rewriting the rules of drug discovery or just riding a wave of hype — from Latent Labs' €48M funding round to the real-world limits of fully in silico drug development. I genuinely believe we'll see the first 100% AI-discovered drug hit the market within the next 5–7 years.
4 Dec 2024 · 1 min read
I attended a fascinating panel at Health Tech Forward on Automation in Clinical Trials featuring in-silico trials and digital twins. Speakers from QuantHealth, a leading VC, and United Therapeutics shared how AI is cutting trial lengths, replacing animal models, and opening new doors for orphan disease research.
18 Nov 2024 · 1 min read
Formation Bio, in collaboration with Sanofi and OpenAI, has introduced Muse, an AI-powered tool designed to optimize patient recruitment in clinical trials. I think it will be fascinating to watch how this three-party collaboration — Big Pharma, Health Tech, and Large Tech — evolves, and I wouldn't be surprised to see more of these partnerships emerge in the coming year.
20 Aug 2024 · 1 min read
I'm curious to see how the AI drug discovery space will evolve following the Recursion/Exscientia merger — and I'd personally bet on the traditional biotech drug-development model with AI enablement, rather than a pure SaaS or CRO play.
1 May 2024 · 2 min read
I just got back from two packed days at LSX2024 in London, where I joined panels on pharma's path to launching digital health products and shared how QuantHealth will transform clinical trial design. Here are my key takeaways from the healthtech track.